MintNeuro announces partnership deal with Motif Neurotech — May 1, 2026 commercial BCI ecosystem expansion
Summary
MintNeuro — the UK company developing ultra-miniaturized wireless neural interface chips — announced a commercial partnership deal with Motif Neurotech on May 1, 2026, as noted in the Neurotech Futures Representations analysis as the third major BCI ecosystem commercial deal of the year (joining Precision+Medtronic Q1 and Science+Neurosoft Q1). The MintNeuro-Motif partnership is the first commercial chip supply deal between a neural interface chip provider and a psychiatric BCI company. MintNeuro's ultra-miniaturized chips are designed for wireless power delivery and data transmission in sub-centimeter neural implants — exactly the capabilities required for Motif's DOT device.
Why it matters
MintNeuro supplying Motif Neurotech is the first commercial chip-to-psychiatric-BCI supply chain deal in the field's history. It demonstrates that BCI chip companies are reaching commercial viability as suppliers to device manufacturers — the semiconductor infrastructure layer of the BCI ecosystem is forming. Three major BCI commercial partnerships in Q1+Q2 2026 (Precision+Medtronic, Science+Neurosoft, MintNeuro+Motif) signal the BCI ecosystem is maturing from individual company development to industry-level supply chain formation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial